miR-101-3p induces vascular endothelial cell dysfunction by targeting tet methylcytosine dioxygenase 2

Qiaoli Chen,Xiaoye Li,Lingjun Kong,Qing Xu,Zi Wang,Qianzhou Lv
DOI: https://doi.org/10.1093/abbs/gmz154
IF: 3.7
2020-01-01
Acta Biochimica et Biophysica Sinica
Abstract:Endothelial cell (EC) dysfunction represents an early key event in atherosclerosis. Recently, MicroRNAs have been demonstrated to regulate EC function. miR-101-3p has been discovered to regulate cell apoptosis and proliferation in cardiovascular diseases. Therefore, the aim of the current study was to clarify whether miR-101-3p regulates the dysfunction of vascular endothelial cells. In this study, the transfection of human umbilical vein endothelial cells (HUVECs) with miR-101-3p mimic induced reactive oxygen species (ROS) production, EC dysfunction, and activated nuclear factor-kappa B (NF-kappa B), whereas transfection with miR-101-3p inhibitor alleviated these events. The antioxidant N-acetylcysteine alleviated miR-101-3p-induced EC dysfunction. Moreover, we observed that miR-101-3p inhibited the expression of tet methylcytosine dioxygenase 2 (TET2) at the posttranscriptional level, resulting in increased ROS production and activated NF-kappa B. TET2 overexpression inhibited ROS production, EC dysfunction, and NF-kappa B activation in miR-101-3p-transfected HUVECs. These results indicate that miR-101-3p induces EC dysfunction by targeting TET2, which regulates ROS production, EC dysfunction, and NF-kappa B activation. Taken together, our current study reveals a novel pathway associated with EC dysfunction. The modulation of miR-101-3p and TET2 expression levels may serve as a potential target for therapeutic strategies for atherosclerosis.
What problem does this paper attempt to address?